[News] Daratumumab for untreated multiple myeloma
Results from a randomised phase 3 trial show that the addition of daratumumab to the standard treatment regimen of bortezomib, melphalan, and prednisone improves progression-free survival in patients with multiple myeloma who are ineligible for stem-cell transplantation.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research
More News: Cancer & Oncology | Myeloma | Prednisone | Stem Cell Therapy | Stem Cells | Transplants | Velcade